Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects various organs and tissues worldwide. The development and activity of SLE involve a combination of genetic predisposition, environmental triggers, and hormonal factors. A complex interplay of factors, including impaired apoptotic clearance, dysregulated immune responses, complement activation, immune complex formation, and tissue inflammation, contributes to the self-sustained autoimmune process.

The precise mechanisms underlying SLE pathogenesis are still not fully understood, resulting in a lack of effective and low side-effect therapies for the disease. In recent years, mesenchymal stem cell (MSC) therapy has gained increasing attention as a potential treatment for autoimmune diseases, including SLE. MSC therapy has shown promise in improving the signs and symptoms of refractory SLE by promoting the proliferation of Th2 and Treg cells (immune cells involved in regulating immune responses) and inhibiting the activity of Th1, Th17, and B cells, among others. However, it is important to note that MSC therapy may not be effective for all SLE patients, and this variability could be related to factors associated with either the MSCs themselves or individual patient characteristics.

Systemic Lupus Erythematosus

Citations and Scientific References

Our medical unit is highly esteemed for partnering globally with fellow researchers on scientific studies and contributing to respected scientific journals.

View References